{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-008503","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.280772+00:00","generated_at":"2026-06-26T11:33:30.934914+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interpace 2021 rev $41.3M (+28%), net loss improves to -$14.9M; CMS reversal on thyroid tests","bullets":["Full year 2021 net revenue $41.3M, up 28% YoY; Q4 revenue $10.9M, up 13% YoY.","Net loss improved to $(14.9)M from $(26.5)M; Adjusted EBITDA $(5.1)M vs $(15.4)M.","Cash collections $43.1M, up 31%, outpacing revenue; DSO decreased 40% to 54 days.","CMS retroactively reversed Jan 2022 billing policy for ThyGeNEXT/ThyraMIR; cash collections may be delayed.","Appointed Dr. Vijay Aggarwal to board, replacing Eric B. Lev, effective Feb 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-008503","json":"https://secwatch.observer/filing/0001493152-22-008503.json","markdown":"https://secwatch.observer/filing/0001493152-22-008503.md","text":"https://secwatch.observer/filing/0001493152-22-008503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222008503/0001493152-22-008503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222008503/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T11:33:30.934914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}